NEW HAVEN, Conn., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it will host a live webcast of its inaugural Analyst Day on Thursday, September 27, 2012 beginning at 1:00 p.m. Eastern Time.
The senior management team, led by Michael Kishbauch, President and Chief Executive Officer of Achillion, will review Achillion's hepatitis C (HCV) programs and future clinical development plans. In addition, presentations are expected to be made by Alan Perelson, Ph.D., Senior Fellow, Los Alamos National Laboratory; Douglas Dieterich, M.D., Professor of Medicine, Liver Diseases, Mount Sinai School of Medicine; and Fred Poordad, M.D., Chief Medical Officer of the Texas Liver Institute / Alamo Medical Research; with Q&A sessions facilitated by Kurt Graves, Director of Achillion, and Chairman, President and Chief Executive Officer of Intarcia Therapeutics.
The webcast will be accessible from the Investor Relations page on the Company's website at http://www.achillion.com . A replay of the webcast will be archived on the Company's website beginning approximately two hours following the live event.About Achillion Pharmaceuticals Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
CONTACT: Company Contact: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 firstname.lastname@example.org Media: Christin Culotta Miller Ogilvy PR Tel. (646) 229-5178 email@example.com Investors: Mary Kay Fenton Achillion Pharmaceuticals, Inc. Tel. (203) 624-7000 firstname.lastname@example.org Investors: Seth Lewis The Trout Group, LLC Tel. (646) 378-2952 email@example.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts